All In Biotech

Drug Trial Radar · NCT00216827

Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis

Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle, and the Gel Vehicle Alone in Scalp Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,485 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,485

Actual

Start

Nov 2004

Primary completion

Not stated

Study completion Sep 2005

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50 mcg/g in the gel vehicle or the gel vehicle used alone in patients with scalp psoriasis. The primary outcome is the proportion of patients with absence of disease or very mild disease after 8 weeks of treatment.

Conditions

  • Psoriasis of Scalp

Interventions

  • Calcipotriol plus betamethasone dipropionate (LEO80185 gel)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall disease severity according to investigator's assessment at week 8

Locations

8 sites in 8 countries. Site status is shown where the registry gives one.

  • FRCPC, Centre de Recherche Dermatologique du Quebec Metropolitain

    Québec, Canada

  • Roskilde Hospital, Division of Dermatology

    Roskilde, Denmark

  • Hôpital de l'Archet, Service de Dermatologie

    Nice, France

  • Hudlegekontoret

    Sandvika, Norway

  • Hospitais da Universidade de Coimbra, Servico de dermatologia

    Coimbra, Portugal

  • Hospital Virgen de la Macarena, Servicio de Dermatología

    Seville, Spain

  • Akademiska Sjukhuset, Hudkliniken

    Uppsala, Sweden

  • Western Infirmary, Dermatology Department

    Glasgow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.